重組蛋白市場規模、佔有率和成長分析（按產品、按應用、按地區）：產業預測（2024-2031）

2022 年全球重組蛋白市場規模約為 22 億美元，高於 2023 年的 23.6 億美元，預測期內（2024-2031 年）複合年成長率為 7.2%，到 2031 年預計將達到41.1億美元。

預計從 2023 年到 2030 年，全球重組蛋白市場將以顯著的 CAGR（年複合成長率）成長。這種快速成長是由遺傳技術的進步所推動的，例如編碼序列的分離以及將這些序列克隆到表達質體載體中。大多數重組治療蛋白是使用微生物、酵母或動物細胞培養物合成的，對於研究蛋白質-蛋白質相互作用至關重要。重組蛋白的多功能性擴展到多種應用，包括清潔劑、美容產品、食品補充品、食品製造、診斷、疫苗和治療。推動市場擴張的因素包括對醫療機構研發投資的增加、慢性病的流行以及針對病毒感染的監管措施的日益重視。研發投資和對創新治療解決方案的需求的結合正在推動市場格局的強勁成長，為希望利用生物技術和醫學進步的利益相關人員提供了重要的機會。隨著市場的成熟，我們期望看到更豐富的產品組合、改進的生產過程和更廣泛的應用，這表明重組蛋白將在科學研究和治療開發中發揮關鍵作用。

目錄

介紹

• 分析目的
• 定義
• 市場範圍

分析方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況及展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 價格分析
• 技術分析
• 價值鏈分析
• 專利分析
• 客戶和購買標準分析
• 監管分析
• PESTEL分析

重組蛋白市場：依產品

• 市場概況
• 細胞激素/生長因子
  • 干擾素(IFN)
  • 白細胞介素(IL)
  • 其他
• 抗體
• 免疫查核點蛋白
• 病毒抗原
• 酵素
  • 激酶
  • 代謝酵素
  • 其他
• 重組調節蛋白
• 荷爾蒙
• 其他

重組蛋白市場：依應用分類

• 市場概況
• 藥物發現/開發
  • 生物製藥
  • 疫苗
  • 細胞/基因治療
• 研究
  • 學術研究
  • 生物技術研究
• 生物製藥製造
• 診斷
• 其他用途

重組蛋白市場：依宿主細胞分類

• 市場概況
• 哺乳動物系統
• 昆蟲細胞
• 酵母/真菌
• 細菌細胞
• 其他宿主細胞

重組蛋白市場：依最終用戶分類

• 市場概況
• 製藥和生物製藥公司
• 生技公司
• 學術研究所
• CRO（藥物委外研發機構）
• 其他最終用戶

按地區分類的重組蛋白市場規模

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Bio-Techne（美國）
• 賽默飛世爾科技公司（美國）
• 默克公司（德國）
• 丹納赫公司（美國）
• 上元科技股份有限公司 (台灣地區)
• BioLegend 公司（美國）
• Bio-Rad 實驗室公司（美國）
• BPS Bioscience, Inc.（美國）
• 恩佐生物化學公司（美國）
• 金斯瑞（中國）
• Miltenyi Biotec BV & Co. KG（德國）
• Proteintech Group, Inc.（美國）
• 義翹神州 (中國)
• ACROBiosystems 集團（美國）
• 英傑華系統生物公司（美國）
• 賽多利斯 CellGenix GmbH（德國）
• Icosagen（美國）
• 神經組學（美國）
• ProSpec-Tany TechnoGene Ltd.（以色列）
• ProteoGenix SAS（法國）

Global Recombinant Proteins Market size was valued at around USD 2.20 billion in 2022 and is expected to rise from USD 2.36 billion in 2023 to reach a value of USD 4.11 billion by 2031, at a CAGR of 7.2% over the forecast period (2024-2031).

The global recombinant protein market is anticipated to experience significant growth at a strong compound annual growth rate (CAGR) from 2023 to 2030. This surge is driven by advancements in genetic techniques, including the isolation of coding sequences and the cloning of these sequences into expression plasmid vectors. A majority of therapeutic recombinant proteins are synthesized using microbial, yeast, or animal cell cultures, which are essential for investigating protein-protein interactions. The versatility of recombinant proteins extends across various applications, including detergents, beauty products, food supplements, food manufacturing, diagnostics, vaccines, and therapies. Contributing factors to the market's expansion include increasing investments by healthcare organizations into research and development, a rising prevalence of chronic diseases, and a growing emphasis on regulatory measures aimed at combatting viral infections. This confluence of investments in R&D and the demand for innovative therapeutic solutions positions the recombinant protein market for robust growth and offers significant opportunities for stakeholders aiming to capitalize on the evolving landscape of biotechnology and healthcare. As the market continues to mature, we can expect to see enhanced product offerings, improved production processes, and a broader range of applications, underscoring the pivotal role recombinant proteins play in both scientific research and therapeutic development.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Recombinant Proteins market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Recombinant Proteins Market Segmental Analysis

Global Recombinant Proteins Market is segmented by Product, Application, Host cell, End User and region. Based on Product, the market is segmented into Cytokines & Growth Factors (Interferons (IFNs), Interleukins (ILs), Others), Antibodies, Immune Checkpoint Proteins, Virus Antigens, Enzymes (Kinases, Metabolic Enzymes, Others), Recombinant Regulatory Proteins, Hormones, Others. Based on Application, the market is segmented into Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Biopharmaceutical Production, Research (Academic Research, Biotechnology Research), Diagnostics, and Others. Based on Host cell, the market is segmented into Mammalian Systems, Insect Cells, Yeast & Fungi, Bacterial Cells, and Others. Based on End User, the market is segmented into Pharmaceutical & Biopharmaceutical, Academic Research Institutes, Contract Research Organizations, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Recombinant Proteins Market

The Global Recombinant Proteins market is propelled by rising R&D expenditures and increased funding within pharmaceutical and biotechnological sectors, leading to significant advancements in drug development. The heightened emphasis on regulatory compliance has expanded treatment options for rare diseases, such as hemophilia and bleeding disorders, further fueling market growth. The escalating demand for biopharmaceuticals is largely attributed to recombinant proteins, which offer enhanced potency, specificity, and reduced side effects compared to conventional small molecule therapies. Consequently, these factors are catalyzing the development of recombinant protein drugs targeting a diverse array of illnesses, including autoimmune disorders, infectious diseases, and cancer.

Restraints in the Global Recombinant Proteins Market

The Global Recombinant Proteins market faces significant restraints due to intense price competition resulting from an influx of key players introducing similar products in a limited market. This saturation leads to decreasing prices, which, while benefiting consumers, undermines profitability and hampers market growth. Additionally, the sector grapples with a shortage of trained medical professionals proficient in recombinant protein applications and research. This skill gap restricts innovation, development, and the effective utilization of recombinant technologies, further stifling industrial advancement. Together, these factors constrain the market's potential and hinder its ability to reach broader applications and increased revenue streams.

Market Trends of the Global Recombinant Proteins Market

The Global Recombinant Proteins market is witnessing robust growth, particularly within the antibody segment, which is anticipated to expand exponentially due to increased adoption across diverse applications such as therapeutics, diagnostics, and research. This trend is driven by advancements in biotechnology, enabling companies to efficiently identify and produce high-quality antibodies through optimized selection processes and expression systems. The rising demand for monoclonal antibodies in personalized medicine, along with a growing focus on biopharmaceuticals, is further propelling market expansion. As industries seek innovative solutions to healthcare challenges, recombinant proteins are becoming vital assets, solidifying their role in modern medicine and research.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Pricing Analysis
• Technology Analysis
• Value Chain Analysis
• Patent Analysis
• Customer & Buying Criteria Analysis
• Regulatory Analysis
• PESTEL Analysis

Recombinant Proteins Market, By Product

• Market Overview
• Cytokines & Growth Factors
  • Interferons (IFNs)
  • Interleukins (ILs)
  • Others
• Antibodies
• Immune Checkpoint Proteins
• Virus Antigens
• Enzymes
  • Kinases
  • Metabolic Enzymes
  • Others
• Recombinant Regulatory Proteins
• Hormones
• Others

Recombinant Proteins Market, By Application

• Market Overview
• Drug Discovery & Development
  • Biologics
  • Vaccines
  • Cell & Gene Therapy
• Research
  • Academic Research
  • Biotechnology Research
• Biopharmaceutical Production
• Diagnostics
• Other Applications

Recombinant Proteins Market, By Host Cell

• Market Overview
• Mammalian Systems
• Insect Cells
• Yeast & Fungi
• Bacterial Cells
• Other Host Cells

Recombinant Proteins Market, By End User

• Market Overview
• Pharmaceutical & Biopharmaceutical Companies
• Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations
• Other End Users

Recombinant Proteins Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Bio-Techne (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abnova Corporation (Taiwan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioLegend Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BPS Bioscience, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enzo Biochem Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Miltenyi Biotec B.V. & Co. KG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Proteintech Group, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sino Biological Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ACROBiosystems Group (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aviva Systems Biology Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius CellGenix GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Icosagen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neuromics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ProSpec-Tany TechnoGene Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ProteoGenix S.A.S (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments